Detalhe da pesquisa
1.
Circulating Tumor Cells Prediction in Hormone Receptor Positive HER2-Negative Advanced Breast Cancer: A Retrospective Analysis of the MONARCH 2 Trial.
Oncologist
; 29(2): 123-131, 2024 Feb 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-37935631
2.
Immune-Related Adverse Event Likelihood Score Identifies "Pure" IRAEs Strongly Associated With Outcome in a Phase I-II Trial Population.
Oncologist
; 29(2): e266-e274, 2024 Feb 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-37715957
3.
Interplay between ESR1/PIK3CA codon variants, oncogenic pathway alterations and clinical phenotype in patients with metastatic breast cancer (MBC): comprehensive circulating tumor DNA (ctDNA) analysis.
Breast Cancer Res
; 25(1): 112, 2023 10 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-37784176
4.
Unique molecular signatures sustained in circulating monocytes and regulatory T cells in convalescent COVID-19 patients.
Clin Immunol
; 252: 109634, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37150240
5.
Refining risk stratification in HR-positive/HER2-negative early breast cancer: how to select patients for treatment escalation?
Breast Cancer Res Treat
; 192(3): 465-484, 2022 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-35124720
6.
Circulating tumor cells, circulating tumor DNA, and disease characteristics in young women with metastatic breast cancer.
Breast Cancer Res Treat
; 187(2): 397-405, 2021 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-34076801
7.
Next Generation Sequencing (NGS): A Revolutionary Technology in Pharmacogenomics and Personalized Medicine in Cancer.
Adv Exp Med Biol
; 1168: 9-30, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31713162
8.
Early evaluation of risk stratification and clinical outcomes for patients with advanced breast cancer through combined monitoring of baseline circulating tumor cells and DNA.
Clin Cancer Res
; 2024 Jun 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38829582
9.
Cyclin-Dependent Kinase 4/6 Inhibitors Beyond Progression in Metastatic Breast Cancer: A Retrospective Real-World Biomarker Analysis.
JCO Precis Oncol
; 7: e2200531, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37141549
10.
Genetic Alterations Detected by Circulating Tumor DNA in HER2-Low Metastatic Breast Cancer.
Clin Cancer Res
; 29(16): 3092-3100, 2023 08 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37265453
11.
Dynamic Glycoprotein Hyposialylation Promotes Chemotherapy Evasion and Metastatic Seeding of Quiescent Circulating Tumor Cell Clusters in Breast Cancer.
Cancer Discov
; 13(9): 2050-2071, 2023 09 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37272843
12.
Unique molecular signatures sustained in circulating monocytes and regulatory T cells in Convalescent COVID-19 patients.
bioRxiv
; 2022 Mar 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-35378753
13.
Circulating tumour DNA characterisation of invasive lobular carcinoma in patients with metastatic breast cancer.
EBioMedicine
; 86: 104316, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-36332363
14.
Single-Cells Isolation and Molecular Analysis: Focus on HER2-Low CTCs in Metastatic Breast Cancer.
Cancers (Basel)
; 14(1)2021 Dec 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-35008244
15.
Circulating Tumor Cell Clusters Are Frequently Detected in Women with Early-Stage Breast Cancer.
Cancers (Basel)
; 13(10)2021 May 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-34068368
16.
ICAM1 initiates CTC cluster formation and trans-endothelial migration in lung metastasis of breast cancer.
Nat Commun
; 12(1): 4867, 2021 08 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34381029
17.
Evidence for interleukin 17 involvement in severe immune-related neuroendocrine toxicity.
Eur J Cancer
; 141: 218-224, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-33186857
18.
Pharmacological management of male breast cancer.
Expert Opin Pharmacother
; 21(12): 1493-1504, 2020 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-32496137
19.
Preclinical models of breast cancer: Two-way shuttles for immune checkpoint inhibitors from and to patient bedside.
Eur J Cancer
; 122: 22-41, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31606656
20.
Opportunities and challenges of implementing Pharmacogenomics in cancer drug development.
Cancer Drug Resist
; 2(1): 43-52, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-35582141